title: Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection.
abstract: OBJECTIVE
  To compare the efficacy and safety of oral acyclovir (400 mg twice daily) with oral isoprinosine (500 mg twice daily) in the suppression of recurrent genital herpes.
  
  
  METHODS
  Double-blind, double-dummy, randomised, controlled, parallel group trial.
  
  
  METHODS
  13 centres in UK, Belgium and Germany.
  
  
  METHODS
  127 immunocompetent patients with frequently recurring genital herpes.
  
  
  METHODS
  Proportions of patients reporting recurrences, recurrence frequency, and mean duration of lesions during breakthrough recurrences in each treatment group during a 6 month treatment period; time to first recurrence during treatment and follow-up after treatment cessation.
  
  
  RESULTS
  During treatment, acyclovir recipients showed significant differences (p < 0.05) when compared with isoprinosine recipients in terms of a lower proportion reporting recurrences (31% vs 96%), a reduced mean number of reported recurrences per patient (0.6 vs 3.6), a shorter mean duration of breakthrough lesions (6.4 days vs 8.2 days), and a longer mean time (standard error) to first recurrence (143.7 (9.1) days vs 40.5 (5.4) days. The mean time to first recurrence after treatment cessation did not differ between the two groups. As compared with placebo recipients, isoprinosine treated patients had an increased recurrence frequency (3.6 vs 2.5) during treatment, and a shorter time to first recurrence after treatment cessation. All treatments were well tolerated without serious adverse events or toxicity.
  
  
  CONCLUSIONS
  Acyclovir is very effective in suppressing recurrent genital herpes and is clearly superior to isoprinosine which is not clinically useful in the dosage studied.
authors.affiliation: Department of GU Medicine, Royal Hallamshire Hospital, Sheffield, UK.
authors.forename: G R
authors.initials: GR
authors.lastname: Kinghorn
authors.forename: P D
authors.initials: PD
authors.lastname: Woolley
authors.forename: R N
authors.initials: RN
authors.lastname: Thin
authors.forename: J
authors.initials: J
authors.lastname: De Maubeuge
authors.forename: J M
authors.initials: JM
authors.lastname: Foidart
authors.forename: R
authors.initials: R
authors.lastname: Engst
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use*; D000284:Administration, Oral; D004311:Double-Blind Method; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy*; D006801:Humans; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008297:Male; D012008:Recurrence; D013997:Time Factors
chemical_list: D007542:Inosine Pranobex; D000212:Acyclovir